A San Francisco federal court has dismissed a class action lawsuit alleging that Xoma had failed to disclose adequately information relating to a US Food and Drug Administration review of the company's license to market its E5 product for the treatment of Gram-negative sepsis.
Xoma is carrying out a further 1,700-patient Phase III clinical trial, at the request of the FDA, in order to clarify the role of the drug in the clinical setting. The study is expected to conclude in the second half of 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze